Tuesday, October 9, 2007

Cumbre Secures Undisclosed Funding Amount

Dallas, Texas-based Cumbre Pharmaceuticals Inc., a drug manufacturer that develops anti-infective products for the treatment of bacterial infections, announced Tuesday that it recently received new venture financing from its existing investor base. An actual dollar amount was not reported. Cumbre said the funds will be used to partner its lead drug candidates and to develop new ones. The Dallas-based company credited several individuals for the financing, including Dr. David Goeddel, Dr. Steven McKnight, Sam G. Winstead, F. Andrew Bell, William Rieflin and Morton H. Meyerson. Cumbre added that it has completed Phase 1 of its investigational drug CBR-2092 and is actively searching for an investment partner to further its clinical development. More information »